ZOMETA® 4 mg every 3 to 4 weeks has a well-characterised renal safety profile
- Bisphosphonates, as a class, have a well-characterised renal safety profile1
- The use of bisphosphonates has been associated with reports of renal dysfunction1
- The renal safety profile of ZOMETA has been assessed in multiple clinical trials1,2
- — Serious renal adverse events are uncommon
*Grade 3 is defined as serum creatinine >3x upper limit of normal (ULN).
†Grade 4 is defined as serum creatinine >6x ULN.
- Incidence of grade 3 and 4 serum creatinine elevation was comparable to pamidronate2
